Oculis ends $100M ATM prospectus; sales pact with Leerink still active

Rhea-AI Filing Summary

Oculis Holding AG suspended and terminated its at-the-market prospectus that permitted sales of up to $100 million of ordinary shares under its May 8, 2024 sales agreement with Leerink Partners. As of this report, no shares were sold under the ATM prospectus. The underlying sales agreement remains in effect, and any future sales would require a new prospectus, prospectus supplement or registration statement.

Insights

Capital markets and securities counsel

ATM prospectus terminated; no shares sold; agreement intact.

On October 29, 2025, Oculis Holding AG ended its ATM prospectus that had allowed issuance of up to $100 million of ordinary shares through Leerink Partners under a May 8, 2024 sales agreement. The company states no shares were sold under this program.

The termination applies to the ATM prospectus only; the sales agreement remains effective. Any future equity sales under this framework would require filing a new prospectus, prospectus supplement, or registration statement.

This is an administrative update without immediate cash inflow or dilution. Subsequent filings would detail any new program terms if Oculis reactivates an offering path.

Form 6-K: How Foreign Companies Report to the SEC →

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

OF THE SECURITIES EXCHANGE ACT OF 1934

For the Month of October 2025

(Commission File No. 001-41636)

Oculis Holding AG

(Translation of registrant’s name into English)

Bahnhofstrasse 20

CH-6300

Zug, Switzerland

(Address of registrant’s principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒   Form 40-F ☐

INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

On October 29, 2025, the Registrant notified Leerink Partners LLC (“Leerink Partners”) that it was suspending and terminating the sales agreement prospectus supplement, dated May 8, 2024 (the “ATM Prospectus”), relating to the sale of up to $100 million of the Registrant’s ordinary shares, nominal value CHF 0.01 per share (the “Ordinary Shares”), that may be issued and sold pursuant to the sales agreement, dated May 8, 2024, by and among the Registrant and Leerink Partners (the “Sales Agreement”). As of the date of this report, the Registrant has not sold any Ordinary Shares under the ATM Prospectus. The Registrant will not make any sales of its Ordinary Shares pursuant to the Sales Agreement unless and until a new prospectus, prospectus supplement or registration statement is filed. Other than the termination of the ATM Prospectus, the Sales Agreement remains in full force and effect.

Incorporation by Reference

The information contained in this Form 6-K is hereby incorporated by reference into the Registrant’s Registration Statements on Form S-8 (File No. 333-271938 and 333-287806) and Form F-3 (File Nos. 333-271063, 333-278409 and 333-281798).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

						OCULIS HOLDING AG
Date: October 29, 2025						/s/ Sylvia Cheung
						Sylvia Cheung
						Chief Financial Officer

FAQ

What did Oculis (OCS) announce on this Form 6-K?

Oculis suspended and terminated its ATM prospectus with Leerink Partners for ordinary share sales.

How large was the ATM capacity for Oculis (OCS)?

The ATM prospectus covered sales of up to $100 million of ordinary shares.

Did Oculis (OCS) sell any shares under the ATM prospectus?

No. The company reports that no ordinary shares were sold under the ATM prospectus.

Does the sales agreement with Leerink Partners remain in effect?

Yes. Only the ATM prospectus was terminated; the sales agreement remains in full force and effect.

What is required for any future share sales by Oculis (OCS)?

A new prospectus, prospectus supplement, or registration statement must be filed before any sales.

Which registration statements does this 6-K incorporate by reference?

It is incorporated into Oculis’s Forms S-8 (File Nos. 333-271938, 333-287806) and Form F-3 (File Nos. 333-271063, 333-278409, 333-281798).